U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H20NO6P
Molecular Weight 257.2213
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHOLINE ALFOSCERATE

SMILES

C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO

InChI

InChIKey=SUHOQUVVVLNYQR-MRVPVSSYSA-N
InChI=1S/C8H20NO6P/c1-9(2,3)4-5-14-16(12,13)15-7-8(11)6-10/h8,10-11H,4-7H2,1-3H3/t8-/m1/s1

HIDE SMILES / InChI

Molecular Formula C8H20NO6P
Molecular Weight 257.2213
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 1 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Choline alfoscerate (alpha-Glycerylphosphorylcholine or Alpha-GPC) is a nootropic choline-containing phospholipid. Choline alphoscerate increases the release of acetylcholine in rat hippocampus, facilitates learning and memory in experimental animals, improves brain transduction mechanisms and decreases age-dependent structural changes occurring in rat brain areas involved in learning and memory. The compound exerts neuroprotective effects in models of altered cholinergic neurotransmission and of brain vascular injury. In clinical studies choline alphoscerate improved memory and attention impairment, as well as affective and somatic symptoms in dementia disorders. In Europe alpha-GPC is a prescription medication for the treatment of Alzheimer's disease. It is available in two forms; one is taken by mouth, and the other is given as a shot. In the United States alpha-GPC is only available as a dietary supplement, mostly in products promoted to improve memory. Other uses for alpha-GPC include treatment of various kinds of dementia, stroke, and "mini-stroke" (transient ischemic attack, TIA). Alpha-GPC is also used for improving memory, thinking skills, and learning.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Gliatilin
Primary
Gliatilin

Cmax

ValueDoseCo-administeredAnalytePopulation
0.38 μg/mL
1200 mg single, oral
CHOLINE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
3.31 μg × h/mL
1200 mg single, oral
CHOLINE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
5.25 h
1200 mg single, oral
CHOLINE plasma
Homo sapiens

Doses

OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
300-1200 mg daily
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
60M22SGW66
Record Status Validated (UNII)
Record Version